Camizestrant Combination Cuts Risk of Progression in ESR1-Mutant Advanced HR-Positive Breast Cancer in SERENA-6 Trial

Camizestrant Combination Reduced Risk of First and Second Disease Progression in ESR1-Mutant Advanced HR-Positive Breast Cancer in SERENA-6 AstraZeneca has announced updated positive findings from its pivotal Phase III SERENA-6…

Read MoreCamizestrant Combination Cuts Risk of Progression in ESR1-Mutant Advanced HR-Positive Breast Cancer in SERENA-6 Trial

C2N Diagnostics and SouthGenetics Partner to Expand Access to Precivity Across Latin America and the Caribbean

C2N Diagnostics and SouthGenetics Partner to Expand Access to Alzheimer’s Blood Biomarker Testing Across Latin America and the Caribbean C2N Diagnostics, LLC, a specialty diagnostics company focused on advancing blood-based…

Read MoreC2N Diagnostics and SouthGenetics Partner to Expand Access to Precivity Across Latin America and the Caribbean